Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : The 56 Point TA; Charts With an Attitude -- Ignore unavailable to you. Want to Upgrade?

To: Doug R who wrote (16318)	5/5/1998 3:44:00 PM
From: Jon L.	Read Replies (1) \| Respond to of 79383

Doug anyone, could you take a look at CAMH I noticed it yesterday but hesitated to mention it, any idea where it can go. thanks -JON

To: Doug R who wrote (16318)	5/5/1998 3:53:00 PM
From: ivan solotaroff	Respond to of 79383

Doug, I'd have to say TTE has Doug R written all over it. NRMI had Doug R written all over it last Friday. Ivan

To: Doug R who wrote (16318)	5/5/1998 4:49:00 PM
From: Charly	Read Replies (1) \| Respond to of 79383

Doug, one for me, one for you. currently riding the cancer hype. Maybe they can really finally get rid off this one. ENMD with 400 % gain in 2 days seems to be gone, the other horse for the next days(weeks?) is named TCLN. As always: total loaded :-) Dont forget to watch IFCI very close. Could pop up every day on mega contracts ! Best Regards Charly

To: Doug R who wrote (16318)	5/5/1998 7:14:00 PM
From: Instock	Read Replies (1) \| Respond to of 79383

Doug: TA please, if you have time < TCLN > TCLN Cancer news! Largest volume and a price leader today. Should get go deal of evening Media attention. IMO Money line and NBR should both have favoable mentions tonight about TCLN. Cancer News is always HOT news! Techniclone cites cancer technology TUSTIN, Calif., May 5 (Reuters) - Techniclone Corp said Tuesday its vascular targeting agent technology has the potential to kill cancerous tumors by targeting and killing tumor blood vessels. It said its research has yielded several candidates shown to eliminate large tumors in preclinical studies in animals. The biotechnology company said it is committed to preparing compounds for preclinical and clinical development in the vascular targeting field. It expects clinical plans to first focus on treatment of established primary tumors rather than inhibiting growth of recurrent or secondary tumors. Scott